Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.86 |
| ▸ | LTA4H | P09960 | 1/20 | 0.83 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | CCR3 | P51677 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8037018 | 0.98 | SIGMAR1 (0.83) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| Ammonia Solution, Strong SCHEMBL28704893 | 0.98 | SIGMAR1 (0.83) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| SCHEMBL5302082 | 0.98 | LTA4H (0.86) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| SCHEMBL113897 | 0.94 | SIGMAR1 (0.96) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| SCHEMBL10601122 | 0.94 | SIGMAR1 (0.96) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| SCHEMBL20382580 | 0.94 | LTA4H (0.86) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| Hydrochloric Acid SCHEMBL7239522 | 0.94 | LTA4H (0.80) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| SCHEMBL8091557 | 0.92 | SIGMAR1 (1.00) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| SCHEMBL492561 | 0.92 | SIGMAR1 (1.00) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B | |
| SCHEMBL8935099 | 0.92 | SIGMAR1 (0.96) | SIGMAR1LTA4HHRH3SLC6A3GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150963-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 광주과학기술원 | 2024-07-18 | — | — | WO | claimed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
| WO-2024150963-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 광주과학기술원 | 2024-07-18 | — | — | WO | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220111367-A1 | HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-14 | — | — | US | disclosed |
| EP-2867207-B1 | PHENOXYETHYL PIPERIDINE COMPOUNDS | LILLY CO ELI (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8268873-B2 | Use of 1-Cyanobutan-2-yl-1-[3-[3-[3-methoxy-4-(oxazol-5-yl)phenyl]ureido]phenyl] ethylcarbamate, AVN 944, VX-944 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8129409-B2 | Piperidine derivatives and cosmetic compositions thereof | L'OREAL (FR) | 2012-03-06 | — | — | US | disclosed |
| US-7943593-B2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors comprising a substituted carbamate-functional N,N'-diphenylurea of given formula; and an apoptosis-inducing anticancer agent such as methotrexate in a synergistic mixture; treating cancer, tumors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-17 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-5576335-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0665216-A1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
| EP-0452267-A1 | Heterocyclic compounds | CIBA-GEIGY AG (CH) | 1991-10-16 | — | — | EP | disclosed |
| EP-0174565-B1 | PIPERIDINE DERIVATIVES AND FUNGICIDAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR COMBATING FUNGI | BASF Aktiengesellschaft (DE) | 1989-10-25 | — | — | EP | disclosed |
| US-4673683-A | Fungicidal piperidine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | disclosed |
| EP-0174565-A2 | Piperidine derivatives and fungicidal compositions containing them, and process for combating fungi | BASF Aktiengesellschaft (DE) | 1986-03-19 | — | — | EP | disclosed |
| EP-0031885-B1 | BASIC ETHERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | MERCK PATENT GmbH (DE) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220111367-A1 | HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME | SUV39H2, SUV39H1, HRH3 | SIGMAR1 1530/4885LTA4H 3510/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.